IGF-1 DES

IGF-1 DES is a real, well-studied cousin of insulin-like growth factor 1 (IGF-1, a natural growth hormone the body makes). It is a little shorter than the natural hormone and packs more of a punch in the lab. You’ll see it sold “for research use only” and pitched for building muscle and losing fat — but no human study backs up any of those uses.

What it is

The natural form of IGF-1 is a hormone built from 70 amino acids (the small building blocks that make up proteins). Your body makes most of it in response to growth hormone. IGF-1 DES — the longer name is des(1-3)IGF-I — is a 67-piece version that’s missing the first three amino acids at one end (a short stretch called the Gly-Pro-Glu tripeptide). It isn’t just something cooked up in a lab, either: it shows up in nature, and it was first pulled from cow colostrum (the first milk after birth), human brain tissue, and pig uterus, where it forms when the full-length IGF-1 gets snipped.

Losing that little tail — and in particular the glutamic acid in the third spot — makes it much worse at clinging to IGF-binding proteins (IGFBPs, the carrier molecules that normally grab most of the IGF-1 floating in your blood and keep it switched off). With less of it tied up by those carriers, the DES form is more free to plug into the IGF-1 receptor (the docking site on cells that triggers growth). In cell-culture studies it’s reported to be more potent than regular IGF-1 at pushing cells to grow and multiply. You’ll often see a “~10x” number tossed around; that comes from lab-dish (in-vitro) work and is best taken as a rough “roughly ten times” ballpark, not an exact figure. The key point: it works through the very same receptor and the same growth-signaling routes inside the cell (called PI3K-Akt and MAPK) as ordinary IGF-1. It’s basically a more-available version of a hormone we already know — not a brand-new mechanism.

You’ll also see a half-life of about 20 to 30 minutes quoted (half-life means how long it takes the body to clear out half of a dose). That number comes from sellers and secondhand sources, not a confirmed human study, so treat it as unverified.

The claims

Marketing materials say IGF-1 DES builds muscle, speeds up fat loss, and helps with recovery and tissue repair. They often point to its greater potency compared with natural IGF-1 — as if that extra potency had already been shown to produce real results in people.

What the evidence actually shows

The basic mechanism is real, and the early animal data is genuine. In a 1992 rat study, des(1-3)IGF-I and the related LR3-IGF-I were about 2.5 times more potent than intact IGF-1 at reversing muscle wasting and nitrogen loss in rats treated with dexamethasone (a steroid that breaks down muscle). A 1996 review lays out the truncated form’s stronger lab-dish potency and its weaker binding to those IGFBP carriers, with growth effects showing up especially in gut tissue in animals.

But that’s where the evidence runs out. There appear to be no peer-reviewed human trials — for effectiveness or safety — testing IGF-1 DES for weight loss, muscle building, or metabolic disease. There’s no listing on ClinicalTrials.gov and no published human trial under the DES name. The only steady stream of human-related research is anti-doping chemistry: methods built to detect des(1-3)IGF-I (and LongR3-IGF-I) in human blood plasma. In other words, that work shows how to find the substance in a person — not what it actually does for them.

It helps to keep two things apart. The full-length lab-made version of IGF-1 (called mecasermin, sold as Increlex) is an approved drug for severe primary IGF-1 deficiency. But that approval covers a different molecule and does not stretch to the DES variant. And potency in animals doesn’t reliably predict what happens in people. As of mid-2026, the honest summary is that the human evidence for IGF-1 DES isn’t just thin — it’s missing.

Legal and regulatory status

IGF-1 DES is not an approved drug anywhere. No regulator — not the FDA, the EMA, or any other — has cleared it for weight loss, muscle, or metabolic use. It’s sold as a “research use only” chemical, a label that limits lawful sale to genuine laboratory research. That label is not a green light for human use.

In sport, IGF-1 and its close relatives are banned at all times — both in and out of competition — under the World Anti-Doping Agency’s Section S2 (which covers peptide hormones, growth factors, related substances, and mimetics). That section spells out “IGF-1, mecasermin, and its analogues.” USADA says every outside source of IGF-1 is banned at all times, and the WADA-accredited detection research specifically names des(1-3)IGF-I and LongR3-IGF-I as targeted relatives. This is a flat ban, not just something being watched. (By contrast, GLP-1 receptor drugs like semaglutide and tirzepatide are not banned; they were added to WADA’s 2026 Monitoring Program as of 1 January 2026.)

Safety

There’s no established safety record for IGF-1 DES in people — no dosing data, no long-term data, and no controlled human safety studies for the DES form. So any claim that it’s “safe” is guesswork, not evidence.

The risks we’d expect come from what we know about IGF-1 biology in general, not from any DES-specific trial. Because IGF-1’s signaling overlaps with how insulin works, low blood sugar (hypoglycemia) is a plausible risk. Because IGF-1 signaling tells cells to grow and divide (it’s “mitogenic”), and because consistently high IGF-1 has been linked in population studies to certain cancers, a more available version raises a theoretical worry about feeding tumor growth. Overgrowth of organs or tissues, and trouble managing blood sugar, are also reasonable cautions to flag. None of these have actually been measured for DES — they’re concerns based on biology, not findings. On top of that, “research use only” material isn’t made to pharmaceutical standards, so there’s no guarantee of what’s really in it, how pure it is, whether it’s sterile, or whether it’s free of endotoxins (bacterial contaminants that can cause fever and other reactions). None of this is medical advice.

Bottom line

IGF-1 DES is a real, well-studied shortened version of IGF-1 with solid early animal data in rodents and cell culture, and it’s more potent than the full hormone in the lab dish. But it has no approved status anywhere, no human trial evidence for weight loss, muscle, or metabolic use, and it’s banned at all times under WADA’s Section S2. Whether it works and whether it’s safe in people are both unknown — honestly, the human evidence simply isn’t there. The hype is running well ahead of what’s actually been shown.

Evidence grade: 3/10 · Animal only.

Sources

• Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I (Ballard et al., 1996) — PubMed
• IGF-I and especially IGF-I variants are anabolic in dexamethasone-treated rats (Tomas et al., 1992) — PubMed
• Insulin-like growth factors 1 and 2 in bovine colostrum: sequences and biological activities compared with a potent truncated form (Francis et al., 1988) — PMC
• IGF-1 and the World Anti-Doping Agency Prohibited List — USADA
• The Prohibited List — World Anti-Doping Agency
• Determination of LongR3-IGF-I, R3-IGF-I, Des1-3 IGF-I and their metabolites in human plasma by LC-MS (Höppner et al., 2017) — PubMed
• Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for anti-doping purposes (Mongongu et al., 2021) — Drug Testing and Analysis
• WADA publishes Prohibited List 2026 (semaglutide and tirzepatide on the 2026 Monitoring Program) — NADA